RU93049153A - TREATMENT BY FATTY ACIDS - Google Patents

TREATMENT BY FATTY ACIDS

Info

Publication number
RU93049153A
RU93049153A RU93049153/14A RU93049153A RU93049153A RU 93049153 A RU93049153 A RU 93049153A RU 93049153/14 A RU93049153/14 A RU 93049153/14A RU 93049153 A RU93049153 A RU 93049153A RU 93049153 A RU93049153 A RU 93049153A
Authority
RU
Russia
Prior art keywords
fatty acids
treatment
linolenic
gamma
acid
Prior art date
Application number
RU93049153/14A
Other languages
Russian (ru)
Other versions
RU2122409C1 (en
Inventor
Фредерик Хорробин Дэвид
Элизабет Рейнольдс Бренда
Original Assignee
Скотиа Холдингс ПЛС
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929217780A external-priority patent/GB9217780D0/en
Application filed by Скотиа Холдингс ПЛС filed Critical Скотиа Холдингс ПЛС
Publication of RU93049153A publication Critical patent/RU93049153A/en
Application granted granted Critical
Publication of RU2122409C1 publication Critical patent/RU2122409C1/en

Links

Claims (1)

Способ повышения усвоения кальция в кишечнике человека и животных заключается в введении жирных кислот (гамма-линоленовой, лигомо-гамма-линоленовой или линоловой кислоты) или самих по себе, или в виде соли, или в другой фармацевтически приемлемой форме, возможно в сочетании с эйкозапентаеновой кислотой, докозогексаеновой кислотой или с другими эйкозановыми жирными кислотами в аналогичном виде. Способ, в частности полезен при лечении остеопороза.The way to increase calcium absorption in the intestines of humans and animals is to administer fatty acids (gamma-linolenic, ligomo-gamma-linolenic or linoleic acid) either by themselves or as a salt or in another pharmaceutically acceptable form, possibly in combination with eicosapentaenoic acid, docosahexaenoic acid or other eicosanoic fatty acids in a similar form. The method is particularly useful in the treatment of osteoporosis.
RU93049153A 1992-08-21 1993-08-20 Treatment with fatty acids RU2122409C1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929217780A GB9217780D0 (en) 1992-08-21 1992-08-21 Fatty acid treatment
GB9217780.7 1992-08-21

Publications (2)

Publication Number Publication Date
RU93049153A true RU93049153A (en) 1996-06-10
RU2122409C1 RU2122409C1 (en) 1998-11-27

Family

ID=10720716

Family Applications (1)

Application Number Title Priority Date Filing Date
RU93049153A RU2122409C1 (en) 1992-08-21 1993-08-20 Treatment with fatty acids

Country Status (21)

Country Link
US (1) US5618558A (en)
EP (1) EP0585026B1 (en)
JP (1) JPH06157303A (en)
KR (1) KR940003553A (en)
CN (1) CN1049334C (en)
AT (1) ATE159856T1 (en)
AU (1) AU666747B2 (en)
CA (1) CA2104567A1 (en)
DE (1) DE69315020T2 (en)
DK (1) DK0585026T3 (en)
ES (1) ES2110060T3 (en)
GB (1) GB9217780D0 (en)
GR (1) GR3025898T3 (en)
HK (1) HK1000997A1 (en)
MY (1) MY109928A (en)
NO (1) NO306655B1 (en)
NZ (1) NZ248422A (en)
RU (1) RU2122409C1 (en)
SG (1) SG80536A1 (en)
TW (1) TW323230B (en)
ZA (1) ZA935976B (en)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9325445D0 (en) 1993-12-13 1994-02-16 Cortecs Ltd Pharmaceutical formulations
GB9403855D0 (en) * 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
EP0711503A3 (en) * 1994-11-14 1997-11-26 Scotia Holdings Plc Milk fortified with GLA and/or DGLA
US5804210A (en) * 1996-08-07 1998-09-08 Wisconsin Alumni Research Foundation Methods of treating animals to maintain or enhance bone mineral content and compositions for use therein
GB9617847D0 (en) 1996-08-27 1996-10-09 Scotia Holdings Plc Fatty acid treatment
AU8857298A (en) * 1997-07-16 1999-02-10 Societe Des Produits Nestle S.A. Method for prophylaxis or treatment of bone density loss
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
US6479545B1 (en) * 1999-09-30 2002-11-12 Drugtech Corporation Formulation for menopausal women
EG22407A (en) * 2000-02-17 2003-01-29 Iams Company Method for improving bone modeling and chondrocyte functioning in growing canines
US7635692B2 (en) 2001-03-15 2009-12-22 Dsm Ip Assets B.V. Composition for the prevention of osteoporosis comprising a combination of isoflavones and polyunsaturated fatty acids
CA2442692A1 (en) * 2001-03-30 2002-10-10 The Nisshin Oillio, Ltd. Bone metabolism improving agents
US7098352B2 (en) * 2001-11-16 2006-08-29 Virtus Nutrition Llc Calcium salt saponification of polyunsaturated oils
WO2005063231A2 (en) * 2003-12-31 2005-07-14 Igennus Limited Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or esther thereof
EP1765964A4 (en) * 2004-04-30 2007-11-07 Polyunsaturated fatty acid monovalent and divalent metal salt synthesis
EP1968402A2 (en) * 2005-10-07 2008-09-17 Ocean Nutrition Canada Limited Salts of fatty acids and methods of making and using thereof
DE102007022694A1 (en) * 2007-05-11 2008-11-13 Humana Milchunion Eg Milk fat milk protein composition to improve calcium absorption
DE102007039310A1 (en) * 2007-08-13 2009-02-19 Eberhard-Karls-Universität Tübingen Universitätsklinikum Composition for the prophylaxis and treatment of osteoporosis
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
EP3578177A1 (en) 2008-09-02 2019-12-11 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
KR20140007973A (en) 2009-02-10 2014-01-20 아마린 파마, 인크. Methods of treating hypertriglyceridemia
NZ624963A (en) 2009-04-29 2016-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
BRPI1011876B1 (en) 2009-04-29 2020-03-31 Amarin Pharma, Inc. STABLE PHARMACEUTICAL COMPOSITIONS UNDERSTANDING EICOSAPENTAENOIC ETHYLACID (ETHYL-EPA) AND USE OF THE SAME TO TREAT OR PREVENT A CARDIOVASCULAR DISEASE
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
CN102625847A (en) 2009-06-15 2012-08-01 阿马里纳制药公司 Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
AU2010298222B2 (en) 2009-09-23 2017-01-05 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
CA3043081C (en) * 2010-03-04 2020-02-11 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating and/or preventing cardiovascular disease
US8178707B2 (en) 2010-03-25 2012-05-15 Jost Chemical Company Co-precipitated salts of fatty acids
CN101978949A (en) * 2010-11-16 2011-02-23 王京南 Gamma-linolenate fat emulsion intravenous injection and preparation method thereof
AU2011336856A1 (en) 2010-11-29 2013-07-04 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
ES2891473T3 (en) 2012-01-06 2022-01-28 Amarin Pharmaceuticals Ie Ltd Compositions and methods for reducing high sensitivity levels (hs-CRP) in a subject
SG10201913645RA (en) 2012-06-29 2020-03-30 Amarin Pharmaceuticals Ie Ltd Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US8728546B1 (en) 2013-03-15 2014-05-20 Swing Aerobics Licensing, Inc. Medicament for treatment of cancer, cardiovascular diseases and inflammation
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
KR102391827B1 (en) 2014-06-04 2022-04-27 디에스 바이오파마 리미티드 Pharmaceutical compositions comprising dgla and use of same
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
MX2018014140A (en) * 2016-06-01 2019-02-25 Nestec Sa Composition for use in the prophylaxis of allergic disease.
US10966951B2 (en) 2017-05-19 2021-04-06 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
MA51765A (en) 2018-09-24 2020-12-16 Amarin Pharmaceuticals Ie Ltd METHODS OF REDUCING THE RISK OF CARDIOVASCULAR EVENTS IN A SUBJECT
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
US11986452B2 (en) 2021-04-21 2024-05-21 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1417119A (en) * 1972-11-30 1975-12-10 Thiele G H Process for treating bones
GB8621816D0 (en) * 1986-09-10 1986-10-15 Efamol Ltd Therapeutic composition
JPH0625057B2 (en) * 1987-12-14 1994-04-06 日本油脂株式会社 Bone formation promoter
GB9112052D0 (en) * 1991-06-05 1991-07-24 Efamol Holdings Fatty acid treatment

Similar Documents

Publication Publication Date Title
RU93049153A (en) TREATMENT BY FATTY ACIDS
DE69315020D1 (en) Use of fatty acids to increase calcium absorption in the intestine
DE60000133D1 (en) ESSENTIAL FATTY ACIDS FOR PREVENTING CARDIOVASCULAR SEASONS
ES2066044T3 (en) FORMULATED FOOD AND ITS PREPARATION PROCEDURE.
GB2218984B (en) Process for preparing high-concentration mixtures of polyunsaturated fatty acids & their esters and their prophylactic or therapeutic uses
RU92016445A (en) APPLICATION OF ISOXOXOL-4-CARBOXYLIC ACID AMIDES AND HYDROXYALKYLIDENANICANE ACID AMIDES
ES2117390T3 (en) SALTS OF A POLYINSATURATED FATTY ACID AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM.
CA2159058A1 (en) Inhibition of helicobacter
ATE43242T1 (en) PHARMACEUTICAL OR DIETETIC COMPOSITION WITH HIGH ANTITHROMBOTIC AND ANTIARTERIOSCLEROTIC ACTION.
DE69114498D1 (en) SHORT-BED, SIMPLY UNSATURATED FATTY ACIDS, AND PHARMACEUTICAL COMPOSITIONS AND THEIR APPLICATIONS.
KR930000114A (en) Treatment with fatty acids
ES2149253T3 (en) MEDICATIONS BASED ON DOCOSAHEXAENOIC ACID AS ANTIGREGANT PLATELET AGENTS AND AGAINST BRAIN DEFICIENCY IN ESSENTIAL FATTY ACIDS AND PREPARATION PROCEDURES.
ES2045120T3 (en) METHOD FOR PREPARING A MEDICATION FOR THE TREATMENT OR PREVENTION OF LOSS OF MEMORY.
FI863976A (en) THERAPEUTIC COMPOSITION.
DE68926115D1 (en) METHOD FOR TREATING ACNE
EP0302481A3 (en) Use of free fatty acids for the manufacture of a medicament for treatment of diabetes mellitus
RU93049092A (en) TREATMENT BY FATTY ACIDS
ES2082390T3 (en) GAMMA-LINOLENIC ACID FOR THE PREPARATION OF A MEDICATION TO PREVENT THE REOCLUSION OF THE ARTERIES.
MA20097A1 (en) PROCESS FOR THE PREPARATION OF NIFLUMIC ACID MORPHOLINEOTYL ESTER DINIFLUMATE FOR THERAPEUTIC USE AS ANALGESIC AND ANTI-INFLAMMATORY.
KR890009868A (en) Trometamine salt of 1-methyl-β-oxo-α- (phenylcarbamoyl) -2-pyrrolepropionitrile
ATE79750T1 (en) ANTI-CANCER PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF CANCER.
JPS5786254A (en) Healthful food
Wenderoth Aspects of the new eicosanoid-research.).
RU93042731A (en) METHOD FOR TREATING POSTNATAL HYPOTROPHY
RU99106551A (en) APPLICATION OF ARAHIDONIC ACID AND / OR DOCOSAHEXAICAENIC ACID FOR THE PRODUCTION OF A MEDICINE FOR THE TREATMENT OF DYSPRAXIA